Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352184 | 0.91 | TP53 (0.56) | TP53MAPTPOLBTHRBHPGD | |
| SCHEMBL1968497 | 0.91 | TP53 (0.56) | TP53MAPTPOLBTHRBHPGD | |
| SCHEMBL3705491 | 0.89 | PTGES (0.48) | TP53MAPTPOLBTHRBHPGD | |
| SCHEMBL1971802 | 0.83 | HDAC6 (0.52) | HPGDHDAC6NPC1 | |
| SCHEMBL1973982 | 0.82 | HPGD (0.51) | TP53MAPTPOLBHPGDALDH1A1 | |
| SCHEMBL1973636 | 0.81 | HDAC6 (0.47) | TP53MAPTPOLBHPGDHDAC6 | |
| SCHEMBL16318485 | 0.80 | PTGES (0.49) | TP53MAPTPOLBHPGDHDAC6 | |
| SCHEMBL1974468 | 0.80 | PTGES (0.57) | TP53MAPTPOLBHPGDHDAC6 | |
| SCHEMBL1974377 | 0.80 | HPGD (0.48) | TP53MAPTPOLBTHRBHPGD | |
| SCHEMBL1974764 | 0.80 | PTGES (0.50) | TP53MAPTPOLBHPGDHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | claimed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | claimed |
| EP-2334664-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | claimed |
| WO-2010034797-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2334664-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010034797-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034797-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, MAP4 | TP53 651/4885MAPT 515/4885POLB 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.